[6], [7], [8] Among patients with CFRD, small clinical studies have shown mixed results regarding changes in glycemia with CFTR modulators. [9], [10], [11], [12], [13] Recently, the CFTR modulator elexacaftor-tezacaftor-ivacaftor (ETI) was approved for patients aged 6 years and older who have at least one copy of the most common CFTR mutation, F508del. This represents 85 % of the cystic fibrosis population. [14] In phase III trials of ETI, the effects on glucose were not analyzed [8], [15]. Here, CFTR is linked to cystic fibrosis.